Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy
| Autor: | Olufunmilayo I. Olopade, K.A. Mills, Tatyana A. Grushko, Iris L. Romero, Gini F. Fleming, Jessica Hunn, Mohammed Habis, Masha Kocherginsky, Jean A. Hurteau, Obiageli Ezewuiro |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty endocrine system diseases lcsh:Medicine 03 medical and health sciences 0302 clinical medicine Carcinosarcoma Uterine cancer Internal medicine Diabetes mellitus medicine Humans Hypoglycemic Agents lcsh:Science Survival rate Aged Neoplasm Staging Retrospective Studies Multidisciplinary business.industry Endometrial cancer lcsh:R Cancer Retrospective cohort study medicine.disease Prognosis Metformin 3. Good health Cystadenocarcinoma Serous Endometrial Neoplasms Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Cohort lcsh:Q Female Neoplasm Recurrence Local business medicine.drug Research Article Adenocarcinoma Clear Cell Follow-Up Studies |
| Zdroj: | PLoS ONE PLoS ONE, Vol 11, Iss 1, p e0147145 (2016) |
| ISSN: | 1932-6203 |
| Popis: | There is increasing evidence that metformin, a commonly used treatment for diabetes, might have the potential to be repurposed as an economical and safe cancer therapeutic. The aim of this study was to determine whether stage III-IV or recurrent endometrial cancer patients who are using metformin during treatment with chemotherapy have improved survival. To test this we analyzed a retrospective cohort of subjects at two independent institutions who received chemotherapy for stage III-IV or recurrent endometrial cancer from 1992 to 2011. Diagnosis of diabetes, metformin use, demographics, endometrial cancer clinico-pathologic parameters, and survival duration were abstracted. The primary outcome was overall survival. The final cohort included 349 patients, 31 (8.9%) had diabetes and used metformin, 28 (8.0%) had diabetes but did not use metformin, and 291 (83.4%) did not have diabetes. The results demonstrate that the median overall survival was 45.6 months for patients with diabetes who used metformin compared to 12.5 months for patients with diabetes who did not use metformin and 28.5 months for patients without diabetes (log-rank test comparing the three groups P = 0.006). In a model adjusted for confounders, the difference in survival between the three groups remained statistically significant (P = 0.023). The improvement in survival among metformin users was not explained by better baseline health status or more aggressive use of chemotherapy. Overall, the findings in this retrospective cohort of endometrial cancer patients with stage III-IV or recurrent disease treated with chemotherapy indicate that patients with diabetes who were concurrently treated with metformin survived longer than patients with diabetes who did not use metformin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|